Amgen ERISA Litigation Settlement
Case No. 2:07-cv-05442-PSG-PLA

Welcome to the Amgen ERISA Litigation Settlement Website

IMPORTANT UPDATE: The Court granted final approval of the Settlement on April 4, 2017. On May 4, 2017, an appeal to the Court’s final approval was filed with the United States Court of Appeals for the Ninth Circuit. The Settlement is not final until after a full and final disposition of any appeal proceeding, without a reversal or material modification due to the appeal. After such disposition, if you are a member of the Class, you will receive whatever monetary or other benefits are provided to you under the Settlement, without having to file a claim or take any action. We are not able to say how long the appeal process will take. Please be patient.


Your legal rights might be affected if you are a member of the following class:

All persons (“Class Members” or “Participants”) who were participants in or beneficiaries of the Amgen Retirement and Savings Plan and the Retirement and Savings Plan for Amgen Manufacturing, Limited (“Plans”) at any time from May 4, 2004 to March 9, 2007, inclusive (“Class Period”), and whose accounts included investments in the Amgen Stock Fund (“Amgen Stock”) (“Class”).

What is this lawsuit about?

A settlement (the “Settlement”) has been approved by the federal court in a class action lawsuit alleging breaches of fiduciary duties under the Employee Retirement Income Security Act of 1974 (“ERISA”) in connection with the Amgen Retirement and Savings Plan and the Retirement and Savings Plan of Amgen Manufacturing, Limited (collectively, the “Plans”). This Settlement will provide for a payment of $2,750,000.00 to the Settlement Fund. The Settlement Fund, minus Court-approved attorneys’ fees and expenses, costs associated with Class Notice and administration of the Settlement Fund, any Court-approved Case Contribution Award to the Named Plaintiffs, and any taxes owed by the Settlement Fund will be allocated to Class Members whose Plan accounts included investments in the Amgen Stock Fund pursuant to a Plan of Allocation approved by the Court. If you qualify for a payment under the Settlement, you do not need to send in a claim or take any other action unless you object to the Settlement.

 

When and where will the Court decide whether to approve the Settlement?

A Fairness Hearing was held April 4, 2017, before the Honorable Phillip S. Gutierrez. Following the hearing, the Court granted final approval of the Settlement on April 4, 2017. You can obtain a copy of the Final Approval Order on the Case Documents page.

 

How do I obtain more information?

If you would like more information, you may contact the Settlement Administrator by calling toll-free 1-844-318-9823 or mailing a letter to:

Amgen ERISA Litigation
c/o JND Class Action Administration
PO Box 6878
Broomfield, CO 80021
 

Copies of the Settlement Agreement, Notices, and Final Approval Order are available on the Case Documents page. Inquiries should NOT be directed to the Court, the Clerk of the Court, or Defendants.

Key Dates

Date Event
March 21, 2017
(EXPIRED)

Class Member Objection Deadline

April 4, 2017
(EXPIRED)

Submission receipt deadline for not Active Participants
to request in writing that their payment be directly
deposited into a qualified retirement plan account.

April 4, 2017 Fairness Hearing
April 4, 2017 Final Approval Order Granted

For More Information

Visit this website often to get the most up-to-date information.

Mail:
Amgen ERISA Litigation
c/o JND Class Action Administration
PO Box 6878
Broomfield, CO 80021